DDR biomarker and PARP/ATR inhibitor response pipeline. Full GDSC v17 mutations + CNV + MSI + tissue context. POC: Talazoparib HRD Spearman ρ=+0.12 (p=3e-4, n=912); per-drug CV AUC 0.68–0.77.
-
Updated
Apr 29, 2026 - Python
#
parp-inhibitors
Here are 2 public repositories matching this topic...
BiPar Sciences was a Brisbane, California biopharmaceutical company developing a tumor-selective class of PARP (poly ADP-ribose polymerase) inhibitors for cancer therapy. Its lead candidate, BSI-201 (iniparib), was in mid-stage trials for advanced breast, ovarian, and other tumors.
company clinical-trials life-sciences oncology pharmaceuticals apis-json acquired parp-inhibitors biopharmaceutical
-
Updated
Aug 22, 2026
Improve this page
Add a description, image, and links to the parp-inhibitors topic page so that developers can more easily learn about it.
Add this topic to your repo
To associate your repository with the parp-inhibitors topic, visit your repo's landing page and select "manage topics."